Somatostatin Receptor 5 antibody | sstr5
The effects of SST are mediated via five distinct SST receptors (SSTRs). The receptors have similar affinities for natural SST-14 and SST-28, but there are marked differences in affinities towards the synthetic analogues. Somatostatin receptors are expressed by various tissues, notably neuronal, endocrine, gastrointestinal and immune cells, as well as certain tumours, with tumours often expressing more than one subtype in different combinations.
Mouse anti Human Somatostatin Receptor 5 antibody, clone sstr5 specifically recognises SSTR type 5, but none of the other SSTR subtypes. Bio-Rad also has antibodies to SSTR subtypes 1, 3 and 4 (MCA5924, MCA5921, MCA5922) available.
- Target Species
- Product Form
- Purified IgG - liquid
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Carrier Free
- Synthetic peptide, sequence CAHRAAANGLMQTSKL.
- Approx. Protein Concentrations
- IgG concentration 1mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- P35346 Related reagents
- Entrez Gene
- SSTR5 Related reagents
- GO Terms
- GO:0004994 somatostatin receptor activity
- GO:0005887 integral to plasma membrane
- GO:0008285 negative regulation of cell proliferation
- For research purposes only
Applications of Somatostatin Receptor 5 antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Paraffin||1/100||1/250|
- Histology Positive Control Tissue
- Human pancreas
Secondary Antibodies Available
Product Specific References
References for Somatostatin Receptor 5 antibody
Schmid, H.A. et al. (2012) Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.
Neuroendocrinology. 95 (3): 232-47.